ovel studies of postparandial lipoprotein metabolism in lean men and men with the metabolic syndrome

Professor Gerald Watts0 个研究点目标入组 45 人开始时间: 2009年5月29日最近更新: 2020年1月13日

试验速览

暂无简介。

•All men will be aged 20-75yr and be non-smoking. 30 metabolic syndrome (MetS) men with a body mass index (BMI) <40kg/m will be recruited. The metabolic syndrome (MetS) will be defined by National Cholesterol Education Programme (NCEP) criteria as the presence of at least three of the following: waist circumference >102cm, triglycerides >1.7mmol/L, high densily lipoprotein (HDL)-cholesterol <1.05mmol/L, blood pressure >130/>85mm, and fasting glucose >6.1mmol/L. The 15 metabolic syndrome (MetS) men treated with Crestor will have a low density lipoprotein (LDL)-cholesterol <2.5mmol/L.
•15 age-matched normolipidaemic men with a body mass index (BMI) <25kg/m2, waist circumference <102cm, triglycerides <1.0mmol/L, high density lipoprotein (HDL)-cholesterol =1.2 mmol/L, will also be recruited.

•Subjects with plasma LDL-cholesterol >5mmo/L, diabetes mellitus, genetic hyperlipidaemia (e.g. familial hypercholesterolaemia (FH), consumption of >30g alcohol/day, apolipoprotein E2/E2 genotype, macroproteinuria, creatinaemia (>120?mol/L), hypothyroidism, and hepatic dysfunction (aspartate transaminase (AST) or alanine transaminase (ALT) >2x upper limit of normal (ULN), Creatine kinase >3x upper limit of normal (ULN) in Crestor treated subjects, major systemic illness and use of steroids or other agents that may influence lipid metabolism, cardiovascular event within past 6 months, subjects on hypocaloric diets, lactose intolerance or intolerance to cream or eggs, anaemia; any significant illness that in the opinion of reviewing physician would bear on the study (e.g. heart murmur or psychiatric conditions)

发起方

Professor Gerald Watts